WO2019105479A1 - 一种β-内酰胺酶抑制剂的晶型及其制备方法 - Google Patents
一种β-内酰胺酶抑制剂的晶型及其制备方法 Download PDFInfo
- Publication number
- WO2019105479A1 WO2019105479A1 PCT/CN2018/118864 CN2018118864W WO2019105479A1 WO 2019105479 A1 WO2019105479 A1 WO 2019105479A1 CN 2018118864 W CN2018118864 W CN 2018118864W WO 2019105479 A1 WO2019105479 A1 WO 2019105479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- crystal form
- preparation
- solvent
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a novel class of beta-lactamase inhibitors, in particular to a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- bacteria can be resistant to ⁇ -lactam antibiotics. The most important thing is that bacteria can produce enzymes that hydrolyze the ⁇ -lactam ring, causing antibiotics to lose their antibacterial activity. Bacteria can also selectively alter the target of antibiotic action. For example, multi-drug resistance of methicillin-resistant Staphylococcus aureus is associated with the production of new PBP 2a , increased synthesis of PBPs, and decreased drug affinity. The ⁇ -lactamase can rapidly bind to certain enzyme-resistant ⁇ -lactam antibiotics, allowing the drug to stay in the extracellular space of the cytoplasm, failing to reach the target site to exert an antibacterial effect.
- the outer membrane of G-bacteria is not easily permeable to certain ⁇ -lactam antibiotics, resulting in non-specific low-level resistance.
- Bacteria can produce various types of ⁇ -lactamases, which can be classified into four categories A, B, C, and D according to their amino acid and nucleotide sequences. Class A, B, and D enzymes catalyze hydrolysis with serine as the active site, and class B enzymes cleave the ring by one or more metal atoms at its active site.
- the first well-known high-activity beta-lactamase inhibitor is potassium clavulanate, and its combination with amoxicillin has so far been popular in the market.
- Two other important beta-lactamase inhibitors on the market are sulbactam and tazobactam. What these three drugs have in common is that the structure has a highly active ⁇ -lactam ring, which is the active site of the inhibitor. Although the three drugs are hot in the market, their antibacterial spectrum is very narrow. They have only an effect on the A- and D-class ⁇ -lactamases, but are completely ineffective against the K-type enzymes of the C-type enzymes and the A-class.
- the drug contains a novel diazabicyclo ring structure that has a broader spectrum of antibacterial activity than the three older generation beta-lactamase inhibitors described above.
- a large number of new compounds of the diazabicyclo ring are disclosed in the patents of the ⁇ -lactamase inhibitors, including: WO2009133442, WO2009091856, WO2010126820, WO2012086241, WO2013030733, WO2013030735, WO2013149121, WO2013149136, WO2013180197, WO20140191268, WO2014141132, WO2014135931, WO2015063653 , WO2015110885, US20140296526.
- two new drugs, MK-7655 and OP-0595 have entered the clinical stage.
- MK-7655 has entered phase III clinical trial
- OP-0595 has entered phase I clinical.
- OP-0595 is extremely active in vitro and is owned by Roche Pharmaceuticals. Therefore, diazabicyclic inhibitors will be a new direction in the development of ⁇ -lactamase inhibitors.
- Form A of the compound of formula (I) characterized by an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2 theta angles: 16.053 ⁇ 0.2 °, 16.53 ⁇ 0.2 °, 22.782 ⁇ 0.2 °, 25.742 ⁇ 0.2 °.
- Form A of the compound of formula (I) characterized by an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2 theta angles: 16.053 ⁇ 0.2 °, 16.53 ⁇ 0.2 °, 18.501 ⁇ 0.2 °, 21.302 ⁇ 0.2 °, 21.778 ⁇ 0.2°, 22.782 ⁇ 0.2°, 25.742 ⁇ 0.2°, 27.833 ⁇ 0.2°.
- the above A crystalline form has an XRPD pattern as shown in FIG.
- the XRPD pattern analysis data of the above A crystal form is as shown in Table 1:
- the A crystalline form has a differential scanning calorimetry curve having an exothermic peak at 221.11 ⁇ 3 °C.
- the A crystal form described above has a DSC spectrum as shown in FIG.
- the above A crystal form has a thermogravimetric analysis curve with a weight loss of 0.5689% at 194.61 ⁇ 3 °C.
- the TGA spectrum showed a weight reduction of 0.5689% when heated to 194.61 °C, and a large weight loss began to occur after 200 °C.
- Form A does not contain crystal water or a crystallization solvent, and has good thermal stability.
- the DVS spectrum is shown in Fig. 4.
- the results show that the A crystal form has a wet weight gain of 0.2910% at 25 ° C / 80% RH, which is slightly hygroscopic.
- the invention also provides a preparation method of the crystal form of the compound A of the formula (I), comprising:
- the solvent is pure water.
- the present invention also provides the use of the above crystalline form A or the crystalline form obtained by the above preparation method for preparing a ⁇ -lactamase inhibitor for treating bacterial infection.
- the technical features of the present invention are mainly embodied in the introduction of a novel side chain of an oxonium group on the basis of a diazabicyclo ring.
- the group Compared with the amino group, the group has more hydrogen bonding sites and thus has better physicochemical properties such as water solubility; on the other hand, the pKa of the group is 8.83 and the pKa of the amino group is relatively close (such as lysine).
- test data of the compounds provided in the present invention in in vitro and in vivo activity experiments also show that the compound of formula (I) has a better activity advantage than OP-0595.
- the crystal form described in the invention has the technical advantages of easy preparation, good stability, and difficulty in crystal transformation, and is favorable for the production and application of the later drugs.
- intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, combinations thereof with other chemical synthesis methods, and those skilled in the art.
- Well-known equivalents, preferred embodiments include, but are not limited to, embodiments of the invention.
- the present invention employs the following abbreviations: MW for microwave; rt for room temperature; aq for aqueous solution; DCM for methylene chloride; THF for tetrahydrofuran; DMSO for dimethyl sulfoxide; NMP for N-methylpyrrolidone; Ethyl ester; EtOH stands for ethanol; MeOH stands for methanol; dioxane stands for dioxane; HOAc stands for acetic acid; Boc stands for t-butoxycarbonyl, Cbz stands for benzyloxycarbonyl, both are amine protecting groups; Boc 2 O stands for di- Tert-butyl dicarbonate; DIPEA stands for diisopropylethylamine; TEA or Et 3 N stands for triethylamine; BnNH 2 stands for benzylamine; PMBNH 2 stands for p-methoxybenzylamine; KOAc stands for potassium acetate; NaOAc stands for acetic acid
- Test method about 10-20 mg sample for XRPD detection
- Test method The sample ( ⁇ 1 mg) was placed in a DSC aluminum pan for testing, and the sample was heated from 30 ° C to 300 ° C at a heating rate of 10 ° C / min under 50 mL / min N 2 .
- Test method A sample (2 to 5 mg) was placed in a TGA platinum pot for testing, and the sample was heated from room temperature to 210 ° C at a heating rate of 10 ° C/min under a condition of 25 mL/min N 2 .
- Test conditions Samples (10-15 mg) were placed in a DVS sample pan for testing.
- the hygroscopicity evaluation is classified as follows:
- Humidity classification Wet weight gain* deliquescence Absorb sufficient water to form a liquid Very hygroscopic ⁇ W% ⁇ 15% Humidity 15%> ⁇ W% ⁇ 2% Slightly hygroscopic 2%> ⁇ W% ⁇ 0.2% No or almost no hygroscopicity ⁇ W% ⁇ 0.2%
- Figure 1 is an XRPD spectrum of Cu-K ⁇ radiation of the crystalline form of Compound A of formula (I).
- Figure 2 is a DSC chart of the crystalline form of Compound A of formula (I).
- Figure 3 is a TGA spectrum of the crystalline form of Compound A of formula (I).
- Figure 4 is a DVS spectrum of the crystalline form of Compound A of formula (I).
- Figure 5 is a graph showing the results of an experiment of Klebsiella pneumoniae producing a compound of formula (I) against a KPC type ⁇ -lactamase.
- reaction mixture was stirred at room temperature (25 ° C) for 20 hours, then diluted with 30 ml of methylene chloride, washed twice with 15 ml of water, and once with 15 ml of brine, dried over anhydrous sodium sulfate and filtered.
- the crude product was purified on a silica gel column (ethyl acetate / petroleum ether mixture, gradient 30% to 50%) to give compound 1-E.
- the broth microdilution method is used to determine the minimum inhibitory concentration (MIC) of the compound of formula (I) for clinical isolates of carbapenemase-producing strains.
- Susceptibility test According to the method of antimicrobial susceptibility test described in the 2016 edition of the American Society for Clinical and Laboratory Standards (CLSI) document, the MIC of commonly used antibacterial drugs against clinically isolated bacteria was determined by micro-broth dilution method.
- strains of KPC-2 carbapenemase and NDM-1 metalloenzyme were produced, and 6 strains of OXA-type carbapenemase were produced. All strains were clinically isolated Klebsiella pneumoniae.
- Antibiotic concentration range 0.06 ⁇ g/mL-128 ⁇ g/mL, a total of 12 concentrations; enzyme inhibitor concentration: fixed at 4 ⁇ g/mL.
- Drug susceptibility test quality control strains include Escherichia coli ATCC 25922 and ATCC 35218.
- the combination of the compound of the formula (I) and the antibiotic has a strong bacteriostatic action against the clinical isolate of Klebsiella producing KPC-2, NDM-1 or OXA-181 carbapenemase.
- the inhibitory effect of the compound of the formula (I) is significantly superior to that of avivatan.
- mice Female CD-1 mice of about 7 weeks old, weighing 26-28 grams; 150 mg/kg 4 days before cyclophosphamide infection, 100 mg/kg 1 day before; infected bacteria are Klebsiella pneumoniae (ATCC BAA-1705, KPC-2).
- mice Female CD-1 mice were infected with Klebsiella pneumoniae by intranasal instillation. Each mouse was instilled with 50 ⁇ L of bacterial solution through the nasal cavity at a dose of 3.14E+07 CFU per mouse, 2 h, 4 h, 6 h and 8 h after infection. Each group of mice was treated with a corresponding compound or a combination compound by intraperitoneal injection.
- mice in groups 1, 2 and 3 were euthanized, and the lungs were placed in a 50 ml centrifuge tube containing 10 ml of sterile physiological saline, placed on wet ice and transferred to BSL-2 laboratory for CFU counting.
- mice in groups 4, 5 and 6 were euthanized and the procedure was the same as before.
- the lungs were ground using an IKA T10 homogenizer (maximum speed 20S, repeated once).
- the homogenate was diluted in a gradient and placed on a tryptone soy agar plate.
- the cells were placed in a 37-degree incubator for bacterial culture. After 24 hours, the plates were removed and counted on a plate. The number of single colonies grown in each dilution gradient homogenate was calculated, and the amount of bacteria in the lungs of each mouse was calculated therefrom.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
引湿性分类 | 引湿增重* |
潮解 | 吸收足量水分形成液体 |
极具引湿性 | ΔW%≥15% |
有引湿性 | 15%>ΔW%≥2% |
略有引湿性 | 2%>ΔW%≥0.2% |
无或几乎无引湿性 | ΔW%<0.2% |
编号 | 溶剂 | 状态 | 晶型 |
1 | 甲醇 | 悬浊液 | A晶型 |
2 | 乙醇 | 悬浊液 | A晶型 |
3 | 乙腈 | 悬浊液 | A晶型 |
4 | 丙酮 | 悬浊液 | A晶型 |
5 | 乙酸乙酯 | 悬浊液 | A晶型 |
6 | 四氢呋喃 | 悬浊液 | A晶型 |
7 | 环己烷 | 悬浊液 | A晶型 |
8 | 水 | 悬浊液 | A晶型 |
9 | 甲醇-水(体积比1:1) | 悬浊液 | A晶型 |
10 | 甲醇-水(体积比3:1) | 悬浊液 | A晶型 |
11 | 乙醇-水(体积比1:1) | 悬浊液 | A晶型 |
12 | 乙醇-水(体积比3:1) | 悬浊液 | A晶型 |
13 | 异丙醇-水(体积比1:1) | 悬浊液 | A晶型 |
编号 | 溶剂 | 状态 | 晶型 |
1 | 丙酮-水(体积比1:2) | 溶解 | A晶型 |
2 | 乙腈-水(体积比1:1) | 溶解 | A晶型 |
编号 | 溶剂 | 编号 | 溶剂 | 编号 | 溶剂 |
1 | 甲醇 | 10 | 醋酸异丙酯 | 19 | 甲醇-水(1:1) |
2 | 乙醇 | 11 | 叔丁基甲醚 | 20 | 甲醇-水(3:1) |
3 | 异丙醇 | 12 | 四氢呋喃 | 21 | 乙醇-水(1:1) |
4 | 正丁醇 | 13 | 2-甲基四氢呋喃 | 22 | 乙醇-水(3:1)* |
5 | 乙腈 | 14 | 甲苯 | 23 | 乙腈-水(1:1) |
6 | 丙酮 | 15 | 正庚烷 | 24 | 丙酮-水(1:2) |
7 | 丁酮 | 16 | 环己烷 | 25 | 异丙醇-水(1:1) |
8 | 甲基异丁基酮 | 17 | 1,4-二氧六环 | ||
9 | 乙酸乙酯 | 18 | 水 |
Claims (9)
- 式(I)化合物的A晶型,其特征在于其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰:16.053±0.2°,16.53±0.2°,18.501±0.2°,21.302±0.2°,21.778±0.2°,22.782±0.2°,25.742±0.2°,27.833±0.2°。
- 根据权利要求2所述的A晶型,其XRPD图谱如图1所示。
- 根据权利要求1~3任意一项所述的A晶型,其差示扫描量热曲线在221.11±3℃处具有放热峰。
- 根据权利要求4所述的A晶型,其DSC谱图如图2所示。
- 根据权利要求1~3任意一项所述的A晶型,其热重分析曲线在194.61±3℃时失重达0.5689%。
- 根据权利要求6所述的A晶型,其TGA谱图如图3所示。
- 式(I)化合物A晶型的制备方法,包括:(a)将(I)化合物加入溶剂后加热到55~60℃至完全溶解;(b)搅拌下缓慢冷却到0℃;(c)搅拌10~16小时析晶;(d)过滤、抽干;其中,所述溶剂为纯水。
- 根据权利要求1~7任意一项所述的A晶型或者权利要求8所述的制备方法得到的晶型在制备用于治疗细菌感染的β-内酰胺酶抑制剂中的应用。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES18884744T ES2928152T3 (es) | 2017-12-01 | 2018-12-03 | Forma cristalina de un inhibidor de beta-lactamasa y método de preparación de la misma |
CN201880076738.2A CN111417633B (zh) | 2017-12-01 | 2018-12-03 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
JP2020529494A JP6974614B2 (ja) | 2017-12-01 | 2018-12-03 | β−ラクタマーゼ阻害剤の結晶形およびその製造方法 |
US16/767,372 US11180501B2 (en) | 2017-12-01 | 2018-12-03 | Crystal form of β-lactamase inhibitor and preparation method therefor |
CA3084099A CA3084099C (en) | 2017-12-01 | 2018-12-03 | Crystal form of .beta.-lactamase inhibitor and preparation method therefor |
EP18884744.6A EP3719020B1 (en) | 2017-12-01 | 2018-12-03 | Crystal form of beta-lactamase inhibitor and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711251386 | 2017-12-01 | ||
CN201711251386.3 | 2017-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019105479A1 true WO2019105479A1 (zh) | 2019-06-06 |
Family
ID=66665421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/118864 WO2019105479A1 (zh) | 2017-12-01 | 2018-12-03 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11180501B2 (zh) |
EP (1) | EP3719020B1 (zh) |
JP (1) | JP6974614B2 (zh) |
CN (1) | CN111417633B (zh) |
CA (1) | CA3084099C (zh) |
ES (1) | ES2928152T3 (zh) |
WO (1) | WO2019105479A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113292499A (zh) * | 2020-02-24 | 2021-08-24 | 齐鲁制药有限公司 | 一种β-内酰胺酶抑制剂的新制备方法及其中间体 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009133442A1 (fr) | 2008-04-29 | 2009-11-05 | Novexel | Composes azabiycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamase |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
WO2012086241A1 (ja) | 2010-12-22 | 2012-06-28 | Meiji Seikaファルマ株式会社 | 光学活性なジアザビシクロオクタン誘導体およびその製造法 |
WO2012172368A1 (en) | 2011-06-17 | 2012-12-20 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
WO2013030733A1 (en) | 2011-08-27 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
WO2013149136A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | ISOXAZOLE β-LACTAMASE INHIBITORS |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2013180197A1 (ja) | 2012-05-30 | 2013-12-05 | Meiji Seikaファルマ株式会社 | 新規β-ラクタマーゼ阻害剤とその製造法 |
WO2014091268A1 (en) * | 2012-12-11 | 2014-06-19 | Naeja Pharmaceutical Inc. | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2014135931A1 (en) | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
US20140288051A1 (en) * | 2011-12-02 | 2014-09-25 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
US20140296526A1 (en) | 2011-09-13 | 2014-10-02 | Wockhardt Limited | Nitrogen containing compounds and their use |
WO2014191268A2 (de) | 2013-05-27 | 2014-12-04 | Siemens Aktiengesellschaft | Verfahren zum betreiben einer gud-kraftwerksanlage |
WO2015063653A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
CN104768951A (zh) * | 2012-08-25 | 2015-07-08 | 沃克哈特有限公司 | 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途 |
WO2015110885A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6929881B2 (ja) * | 2016-06-03 | 2021-09-01 | チールー ファーマシューティカル カンパニー、リミテッド | 新規なβ−ラクタマーゼ阻害剤 |
-
2018
- 2018-12-03 CA CA3084099A patent/CA3084099C/en active Active
- 2018-12-03 US US16/767,372 patent/US11180501B2/en active Active
- 2018-12-03 JP JP2020529494A patent/JP6974614B2/ja active Active
- 2018-12-03 WO PCT/CN2018/118864 patent/WO2019105479A1/zh unknown
- 2018-12-03 ES ES18884744T patent/ES2928152T3/es active Active
- 2018-12-03 CN CN201880076738.2A patent/CN111417633B/zh active Active
- 2018-12-03 EP EP18884744.6A patent/EP3719020B1/en active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
WO2009133442A1 (fr) | 2008-04-29 | 2009-11-05 | Novexel | Composes azabiycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamase |
WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
WO2012086241A1 (ja) | 2010-12-22 | 2012-06-28 | Meiji Seikaファルマ株式会社 | 光学活性なジアザビシクロオクタン誘導体およびその製造法 |
WO2012172368A1 (en) | 2011-06-17 | 2012-12-20 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
WO2013030733A1 (en) | 2011-08-27 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
US20140296526A1 (en) | 2011-09-13 | 2014-10-02 | Wockhardt Limited | Nitrogen containing compounds and their use |
US20140288051A1 (en) * | 2011-12-02 | 2014-09-25 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2013149136A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | ISOXAZOLE β-LACTAMASE INHIBITORS |
WO2013180197A1 (ja) | 2012-05-30 | 2013-12-05 | Meiji Seikaファルマ株式会社 | 新規β-ラクタマーゼ阻害剤とその製造法 |
CN104768951A (zh) * | 2012-08-25 | 2015-07-08 | 沃克哈特有限公司 | 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途 |
WO2014091268A1 (en) * | 2012-12-11 | 2014-06-19 | Naeja Pharmaceutical Inc. | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2014135931A1 (en) | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2014191268A2 (de) | 2013-05-27 | 2014-12-04 | Siemens Aktiengesellschaft | Verfahren zum betreiben einer gud-kraftwerksanlage |
WO2015063653A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015110885A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane |
Non-Patent Citations (2)
Title |
---|
"U.S. Clinical and Laboratory Standards Institute (CLSI", 2016 |
See also references of EP3719020A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113292499A (zh) * | 2020-02-24 | 2021-08-24 | 齐鲁制药有限公司 | 一种β-内酰胺酶抑制剂的新制备方法及其中间体 |
CN113292499B (zh) * | 2020-02-24 | 2024-05-28 | 齐鲁制药有限公司 | 一种β-内酰胺酶抑制剂的新制备方法及其中间体 |
Also Published As
Publication number | Publication date |
---|---|
CA3084099A1 (en) | 2019-06-06 |
CN111417633A (zh) | 2020-07-14 |
EP3719020B1 (en) | 2022-09-21 |
CA3084099C (en) | 2022-05-17 |
JP6974614B2 (ja) | 2021-12-01 |
CN111417633B (zh) | 2022-05-06 |
US20200385385A1 (en) | 2020-12-10 |
JP2021504416A (ja) | 2021-02-15 |
ES2928152T3 (es) | 2022-11-15 |
EP3719020A4 (en) | 2021-08-04 |
EP3719020A1 (en) | 2020-10-07 |
US11180501B2 (en) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107148417B (zh) | 苯并氮杂*磺酰胺化合物 | |
JP5022909B2 (ja) | 2,4(4,6)ピリミジン誘導体 | |
BG107497A (bg) | Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства | |
EA021367B1 (ru) | Производное пиридин-3-карбоксамида | |
AU2012293329A1 (en) | Quinazoline-2,4-dione derivatives | |
JP2020097526A (ja) | 複素環化合物 | |
AU2012228439A1 (en) | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (SYK) | |
JP6250667B2 (ja) | 新しい抗菌化合物 | |
WO2016040764A1 (en) | Carbonyl linked bicyclic heteroaryl n-benzimidazoles and analogs as antibiotic tolerance inhibitors | |
JP2018529696A (ja) | ヒドロキシアルキルチアジアゾール誘導体 | |
JPWO2009004792A1 (ja) | スルホンアミド化合物及びその結晶 | |
EP3245200A1 (en) | 2-(pyrazin-2-ylcarbonylaminomethyl)benzimidazolium compounds as epithelial sodium channel inhibitors | |
TW201617347A (zh) | 一種jak激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
WO2019105479A1 (zh) | 一种β-内酰胺酶抑制剂的晶型及其制备方法 | |
JP2009516704A (ja) | 新規なプリューロムチリン誘導体およびその使用 | |
CN102224151A (zh) | 新的抗微生物剂 | |
NO309936B1 (no) | 2,7-Substituerte oktahydro-pyrrol[1,2-a]pyrazin-derivater, anvendelse derav, farmasøytisk preparat, samt mellomprodukter for fremstilling av derivatene | |
TWI820266B (zh) | 巨環化合物及其用途 | |
CN107739371A (zh) | 一类四氢咔唑类小分子有机化合物及其在制备抗菌药物中的用途及其制备方法 | |
CN108239098B (zh) | 含四氢吡啶的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 | |
EP3717490B1 (en) | Anti-bacterial heterocyclic compounds and their synthesis | |
CN112239457B (zh) | 一种乙酰基连接的加替沙星-1,2,3-三氮唑-靛红杂合体及其制备方法和应用 | |
WO2023078411A1 (zh) | 氮杂螺环化合物 | |
CN111662351B (zh) | 新奥克梯隆型皂苷元衍生物及制备抗耐药菌药物应用 | |
CN109665994B (zh) | 青花椒碱衍生物及其作为抗菌药物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18884744 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020529494 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3084099 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018884744 Country of ref document: EP Effective date: 20200701 |